(Q42692011)

4 November 2017

Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis (English)

1 reference

4 November 2017

1 reference

1 reference

1 reference

1 reference

Bruce K Birmingham

1

1 reference

4 November 2017

Suzanne K Swan

2

1 reference

4 November 2017

Tom Puchalski

3

1 reference

4 November 2017

Pat Mitchell

4

1 reference

4 November 2017

Connie Azumaya

5

1 reference

4 November 2017

Julie Zalikowski

6

1 reference

4 November 2017

Yi Wang

7

1 reference

4 November 2017

language of work or name

1 reference

1 April 2013

1 reference

Clinical Drug Investigation

4 November 2017

1 reference

4 November 2017

33

1 reference

4 November 2017

4

1 reference

4 November 2017

233-241

1 reference

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

4 November 2017

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Rosuvastatin in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

New insights in uremic toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Effect of chronic renal failure on high-density lipoprotein kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Lipid profile in maintenance haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0071-3

The influence of chronic renal failure on drug metabolism and transport

21 January 2018

1 reference

12 December 2020

Clinical epidemiology of cardiovascular disease in chronic renal disease

1 reference

12 December 2020

Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients

1 reference

12 December 2020

Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.

1 reference

12 December 2020

Downregulation of hepatic cytochrome P450 in chronic renal failure.

1 reference

12 December 2020

HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients

1 reference

12 December 2020

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients

1 reference

12 December 2020

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

1 reference

12 December 2020

The effect of chronic renal failure on drug metabolism and transport

1 reference

12 December 2020

LDL and HDL subclass distribution in patients with end-stage renal diseases

1 reference

12 December 2020

Decreased in vivo metabolism of drugs in chronic renal failure

1 reference

12 December 2020

10.1007/S40261-013-0071-3

Identifiers

DOI

1 reference

4 November 2017

1 reference